WO2009057725A1 - Composition d'extrait de jute tossa traitée par une protéase, procédé de production de la composition et agent anti-hypertenseur ou boisson/aliment comprenant ladite composition - Google Patents

Composition d'extrait de jute tossa traitée par une protéase, procédé de production de la composition et agent anti-hypertenseur ou boisson/aliment comprenant ladite composition Download PDF

Info

Publication number
WO2009057725A1
WO2009057725A1 PCT/JP2008/069818 JP2008069818W WO2009057725A1 WO 2009057725 A1 WO2009057725 A1 WO 2009057725A1 JP 2008069818 W JP2008069818 W JP 2008069818W WO 2009057725 A1 WO2009057725 A1 WO 2009057725A1
Authority
WO
WIPO (PCT)
Prior art keywords
extract
morohaya
treated
enzyme
composition
Prior art date
Application number
PCT/JP2008/069818
Other languages
English (en)
Japanese (ja)
Inventor
Yuji Kubota
Hideki Kano
Takanobu Takihara
Atsuhiro Mitomi
Original Assignee
Ito En, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ito En, Ltd. filed Critical Ito En, Ltd.
Publication of WO2009057725A1 publication Critical patent/WO2009057725A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Definitions

  • the present invention relates to a proteolytic enzyme-treated Morohella extract composition, a method for producing the same, and an antihypertensive agent or food and drink containing the composition.
  • the present invention relates to a proteolytic enzyme-treated Morohella extract composition having a blood pressure lowering action, more specifically, a proteolytic enzyme-treated Morohaya obtained by subjecting Morohaya leaves, Morohaya extract or Morohaya puree to protease extraction. Extract composition, antihypertensive agent containing the proteolytic enzyme-treated moroheia extract composition as an active ingredient, food and drink comprising the proteolytic enzyme-treated morohea extract composition, and the proteolytic agent
  • the present invention relates to a method for producing an enzyme-treated molhahea extract composition. Background art
  • General therapy is a method of treatment by exercise therapy such as weight loss, alcohol saving, aerobic exercise, etc., and dietary therapy such as salt reduction, and is the basis for treatment of essential hypertension.
  • exercise therapy such as weight loss, alcohol saving, aerobic exercise, etc.
  • dietary therapy such as salt reduction
  • pharmacotherapy is a therapy used for hypertension in which blood pressure does not normalize by general therapy, such as when the effects of dietary therapy or exercise therapy are insufficient, or for severe hypertension.
  • Drugs used in pharmacotherapy include calcium antagonists, angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists, diuretics, and sympathetic inhibitors And so on.
  • ACE angiotensin converting enzyme
  • ACE inhibitors are widely known as side effects such as dry cough, dizziness, standing up, nausea, roar, and excessive sedation, which lowers QOL and leads to reduced compliance.
  • tea beverages containing plant-derived peptides are sold as beverages suitable for people with high blood pressure.
  • sesame protein degradation product containing sesame peptide
  • L eu— V a 1-T yr L eu— V a 1-T yr
  • LVY 1-T yr
  • Some have ACE inhibitory action and blood pressure lowering action.
  • dairy lactic acid bacteria beverages with ⁇ -aminobutyric acid (GABA) added are on the market.
  • G A B A is a kind of amino acid, a typical inhibitory neurotransmitter, and has long been known to have a blood pressure lowering effect.
  • milk protein, soy protein, or fish protein contains various ACE inhibitory peptides. Practical use of antihypertensive agents with low toxicity and high safety is being investigated. However, it is included in these natural product-derived peptides The blood pressure-lowering peptide is very small, and there are many that cannot be expected to have a great effect with realistic oral intake, or that have a strong ACE inhibitory activity but a low blood pressure-lowering effect.
  • the causative substances of blood pressure lowering effects are clear, industrially stable production is possible, and blood pressure lowering substances derived from natural products that are more effective and safer than conventional products and contain them Health foods and health drinks are required.
  • Morohaya (scientific name: Corchorus oitorius L.) is a kind of jute that originates in the Mediterranean region centering on Egypt, and is one of the food ingredients that has attracted particular attention in recent years due to its high nutritional value. Moroheiya, when minced or boiled, produces a unique jelly like Otara potato, which contains plant gum and viscous polysaccharides (mucopolysaccharides). Nutritionally, vitamins and minerals are abundant, and in particular, the total strength of rotin and calcium is high. Rotin is about 12 times that of Proccoli, Vitamin B 1 is about 3 times tomato, Vitamin B 2 is about 14 times pepper, It is said that um is about 2.4 times milk and dietary fiber is about 20 times lettuce. For this reason, it has recently been cultivated in Japan, and its dry powder along with fresh leaves is gaining attention as a food material.
  • Morohaya Morohaya powder and Morohaya extract, foods and compositions containing them, and methods for producing the same.
  • Takashi Yamamoto and others have reported a production method for extracting a moroheiya extract by adding an organic acid for the purpose of lowering the viscosity of the moroheia extract for use in beverages (see Patent Document 2).
  • Satoshi Inami and others have reported a composition containing an ethanol precipitate as an active ingredient in the water-soluble fraction of morohea leaves (see Patent Document 3).
  • this active ingredient is dietary fiber.
  • Patent Document 1 Japanese Patent Laid-Open No. 7-1 2 3 9 7 7
  • Patent Document 2 Japanese Patent Laid-Open No. 10-1 9 1 9 2 2
  • Patent Document 3 Japanese Patent Laid-Open No. 7-6 9 9 1 0
  • Patent Document 4 Japanese Patent Laid-Open No. 2 0 0 0-2 6 3 0 5
  • Patent Document 5 Japanese Patent Application Laid-Open No. Hei 11 1 3 2 2 6 6 7
  • Patent Document 6 Japanese Patent Laid-Open No. 2 0 0 3-2 3 1 6 7 5
  • Non-Patent Document 1 J. Dairy Sci. 78: p.777-783
  • Non-Patent Document 2 J. Dairy Sci. 78: 1253-1257
  • Non-Patent Document 3 Food Testing and Research, No. 31, 7 8-7-9, 1 9 9 6 “Morrohair nutrients and angiotensin I-converting enzyme inhibitory activity”, Akihiko Arakawa
  • Non-Patent Document 4 Bulletin of Tokyo Kasei University, Vol. 38 (2), 5 9— 6 3, 1 9 9 8 “Research on ACE inhibitors in foods”, Koichi Kimoto, Emiko Shimizu, Kuroda Yuko
  • Non-Patent Document 5 Journal of the Japanese Society of Dietary Life, Vol. 10, No. 3, 2 0— 2 5, 1 9 9 9 “About antihypertensive substances in foods”, Koichi Kimoto Disclosure of the Invention
  • the object of the present invention is effective for hypertensive patients, particularly essential hypertensive patients, which are said to account for 90%, and is derived from a safe food suitable for long-term use without side effects. It is intended to provide vasodilators or antihypertensive agents, foods and drinks containing these compositions, particularly foods such as health foods and health supplements, or beverages containing them. Furthermore, it is providing the manufacturing method of those compositions. Means for solving the problem
  • the present inventors focused on Morohaya, which has been attracting attention as a food material with high nutritional value in recent years.
  • Proteolytic enzyme treatment of leaves and the like makes it possible to produce a proteolytic enzyme-treated mochahae extract composition having a superior blood pressure lowering action, specifically, vasodilation or vascular relaxation.
  • the present invention has been completed. Specifically, the present invention is as follows.
  • a proteolytic enzyme-treated morohella extract composition having a blood pressure lowering action obtained by treating morohaya with a protease.
  • proteolytic enzyme-treated Morohella extract composition according to 1 above wherein the protease is an endopeptidase.
  • the endopeptidase is an endopeptidase from Bac il lus. 3.
  • a method for producing a proteolytic enzyme-treated moroheiya extract composition comprising adding a protease to moroheiya hydrolyzate and applying enzyme treatment to inactivate the enzyme.
  • the moroheiya hydrolyzate is a morohea leaf solution obtained by adding morohae leaves to water or warm water, moroheiya extract, moroheiya extract solution or moroheia puree obtained by dissolving moroheiya extract powder in water or hot water Of Proteolytic Enzyme-treated Morohella Extract Composition.
  • An antihypertensive agent comprising the proteolytic enzyme-treated moroheiya extract composition as described in 1 to 3 above as an active ingredient.
  • a food or drink comprising the proteolytic enzyme-treated moroheiya extract composition described in 1 to 3 above.
  • the invention's effect is not limited
  • the proteolytic enzyme treatment composition of the present invention is derived from Morohaya whose safety has been confirmed as food, it is extremely safe without side effects and can be taken on a daily basis.
  • the production method is very easy because only protease (protein degrading enzyme) is allowed to act on the leaf of moroheiya, moroheiya extract or moroheia puree obtained by adding water or warm water.
  • protease protein degrading enzyme
  • Morohaya is a plant rich in vitamins, minerals, and dietary fiber and has high nutritional value
  • the proteolytic enzyme of the present invention can be used when compared with a single component that has a blood pressure lowering effect. If you ingest the treatment composition, It is possible to take multiple ingredients at the same time, and further effects can be expected.
  • Moroheiya because it is made from the natural plant Moroheiya, it is inexpensive and highly safe, making it ideal for pharmaceuticals, foods for specified health use, health foods, beverages, etc.
  • FIG. 1 is a graph showing systolic blood pressure fluctuations caused by administration of a moroheia enzyme-treated extract. (Test Example 1)
  • FIG. 3 is a graph showing heart rate variability due to administration of Morohaya enzyme-treated extract. (Test Example 1)
  • Fig. 4 is a graph showing fluctuations in mean blood pressure due to administration of a moroheiya enzyme-treated extract.
  • FIG. 5 is a diagram showing the diurnal variation in systolic blood pressure of the SHR rat. (Test example 1)
  • FIG. 6 is a graph showing the effect of morohaya enzyme-treated extract prepared from morohaya puree on blood pressure fluctuations. (Test Example 2)
  • FIG. 7 is a graph showing the results of measuring the ACE inhibitory activity of Morohaya enzyme-treated extract. (Test Example 3)
  • FIG. 8 is a diagram showing the vasorelaxant action of Morohaya enzyme-treated extract.
  • the proteolytic enzyme-treated Morohella extract composition of the present invention is Proteolytic enzyme, ie, proteaase It can be obtained by acting and extracting.
  • Proteolytic enzyme ie, proteaase It can be obtained by acting and extracting.
  • water or hot water is added to Morohaya leaves from which hard stem portions have been removed, and then steam heating is performed to crush them.
  • hot water of about 10 to 40 times, preferably about 20 to 30 times the weight of distilled water is added to the dried morohea leaves obtained by drying the crushed morohea leaves with hot air. After that, after heat sterilization at a temperature of 95 ° C or higher, cool to an appropriate temperature and maintain the liquid temperature in a water bath, and apply an appropriate amount of peptate dissolved in a small amount of water.
  • zea is added to the dry leaf weight or dry leaf equivalent weight of the raw material. After adding the protease, stir every 10 minutes and hold for 15 minutes to 2 hours, preferably 45 to 90 minutes after adding the protease, and then hold at 95 ° C for 5 minutes.
  • Proteolytic enzyme-treated Morohaya extract composition of the present invention is obtained by inactivating protease, filtering through a sieve having an opening of 85 5 ⁇ ⁇ , and then suction filtration using No. 2 filter paper Can do. Treatment conditions such as solution temperature, enzyme concentration and pH for protease treatment may be adjusted so that the protease to be used works optimally.
  • the proteolytic enzyme-treated Morroheia extract composition thus obtained can be used as it is as a beverage, or in other fruit juices, vegetable juices, and mix juices. Further, it can be made into a concentrated liquid composition by concentration under reduced pressure to an appropriate concentration, and it can be freeze-dried and powdered according to the purpose. These concentrated liquid compositions and powdered enzyme treatment compositions can be used by adding to foods, beverages, etc.
  • the morohaya hydrolyzate as the target of the enzyme treatment is an aqueous solution or hot water solution containing morohaya leaves or morohaya extract as a raw material, and is not particularly limited. Specifically, it is a morohella leaf solution in which morohea leaves are mixed in water or warm water, a morohaya extract solution, a morohaya extract solution or morohya puree in which morohaya extract powder is dissolved in water.
  • any part of the above-ground part except the seeds may be used, but the part of the leaves from which the hard stem part is removed is particularly preferable. It is preferable to use dried leaves obtained by crushing them after steam heating and drying with hot air, etc., but the method for preparing the dried leaves is not particularly limited. Can also be used. It is desirable to treat the dried morohay leaves with water or warm water, more preferably after pulverization. The extraction time varies slightly depending on the extraction temperature, but is 15 minutes to 2 hours, preferably 45 minutes to 90 minutes. In addition to dried leaves, for example, Morohaya extract, which is an extract, Morohaya extract solution obtained by dissolving Morohaya extract powder in water, and Morohaya puree can also be used.
  • the protease enzyme used is not particularly limited, but is preferably an endopeptidase or an endopeptidase-based complex enzyme. A plurality of enzymes can also be used in combination.
  • the proteolytic enzyme or protease used in the present invention is an enzyme that catalyzes a peptide bond hydrolysis reaction. Although it is not particularly limited, it is preferably an end-type enzyme or an end-type complex enzyme. Of these, a proteolytic enzyme produced by Bacillus genus is more preferable. More preferably produced by Bac ill us subt ilis and Bac il lus thermoproteo lyt i cus 2 Proteolytic enzyme. It is also possible to use a combination of multiple enzymes.
  • the pH, treatment temperature, treatment time, and treatment concentration during protease treatment are not particularly limited, but can be appropriately selected depending on the enzyme used. 3 ⁇ 4, ⁇ ⁇ 5 ⁇ 0 to 8.5, more preferably ⁇ ⁇ 5.5 to 7.0, treatment temperature 40 ° C to 70 ° C, preferably 50 ° C to 65 ° C
  • the treatment time is 15 minutes to 2 hours, preferably 45 minutes to 90 minutes
  • the preferred enzyme concentration is 0.001 to 3% by weight, preferably 0. 0 to 2% by weight, more preferably 0.1 to 1.5% by weight.
  • these conditions may be changed depending on the type of enzyme.
  • treatment concentration is 0.1 to 1.0 weight of the dry weight of the chamber. /. Is preferred.
  • treatment concentration is It is preferably 0.1 to 1.0% by weight of the dry weight of moroheiya.
  • the enzyme is deactivated by heating, and solid-liquid separation is performed by any method such as filtration, and the extract is recovered.
  • the enzyme deactivation method is appropriately selected depending on the enzyme used, but can be performed by heating. For example, the enzyme may be left at 95 ° C. to boiling for 5 to 10 minutes.
  • Protein-treated morohea extract composition means a composition obtained by treating morohea with proteolytic enzyme in water or warm water and extracting it. These proteolytic enzyme treatment compositions may be liquid or solid. Protein The white matter-degrading enzyme treatment solution itself, a proteolytic enzyme treatment solution obtained by solid-liquid separation of insoluble components such as stems, a concentrated concentrate obtained by concentrating it, and a powder obtained by freeze-drying them, or solidifying the powder It may be a tablet.
  • Morohaya hydrolyzate that is, Morohaya leaf solution obtained by adding Morohaya leaves to water or hot water, Morohaya extract, Morohaya extract solution or Morohaya extract solution obtained by dissolving Morohaya extract powder in water or warm water.
  • An extract obtained by treating le with a proteolytic enzyme is referred to as a morohea enzyme-treated extract or enzyme-treated extract.
  • the enzyme-treated solution and concentrated solution separated by solid-liquid can be used as beverages as they are or mixed with other soft drinks such as fruit juice vegetable juice.
  • the powder or solid tablet itself can be used as a health food, functional food, health supplement, etc., and can also be used as a compounding ingredient for soft drinks and foods.
  • the proteolytic enzyme-treated moroheiya extract composition obtained in the present invention has a small taste that is peculiar to taste and odor, and therefore can be taken orally in liquid or solid form.
  • the intake varies depending on the age and blood pressure level, but is usually 10 mg to 600 mg at a time in terms of powder, preferably 50 mg to 300 mg, more preferably once 10 mg to l 500 mg.
  • the effect can be obtained by taking 1 to 3 times a day, but the number can be increased if necessary.
  • it when contained in a beverage, it is 50 mg to 600 mg, more preferably 50 mg to 400 mg, per 50 mL.
  • the proteolytic enzyme-treated morohea extract composition obtained in the present invention is itself dried, if necessary, or appropriately mixed with excipients or the like for convenience of formulation, such as powders, granules, tablets, and force-pellants. It can be administered in the form. Also, candy, jelly, tablet confectionery, beverage, soup, candy, rice cracker, Japanese confectionery, frozen confectionery, baked confectionery, etc. It is possible to mix and add to various foods and drinks. Preferably, it may be used by mixing with other foods and drinks, particularly preferably in beverages such as fruit drinks, vegetable juices, fruit vegetable juices, tea drinks, coffee drinks, sports drinks and the like. By doing so, not only the nutrients contained in vegetable juice etc. can be ingested on a daily basis, but also natural products having a blood pressure lowering effect can be ingested naturally for hypertensive consumers.
  • excipients or the like for convenience of formulation, such as powders, granules, tablets, and force-pellants. It can be administered in the
  • a preferred form of food or drink containing the proteolytic enzyme-treated morohea extract composition is a koji, jelly, tablet confectionery, beverage, soup, koji, rice cracker containing the proteolytic enzyme-treated moroheia extract composition.
  • Japanese confectionery, frozen confectionery, baked confectionery, etc. particularly preferably, fruit juice beverage, vegetable juice, fruit vegetable juice, tea beverage, coffee beverage, sports drink comprising the proteolytic enzyme-treated Morohaya extract composition And so on.
  • the examination of the blood pressure lowering effect of the proteolytic enzyme-treated moroheia extract composition of the present invention is to orally administer the moroheia extract of the present invention to a spontaneous hypertension rat and measure the blood pressure before and after administration. It went by.
  • vasodilatory / relaxing action that is, the blood pressure lowering action mechanism of the proteolytic enzyme-treated morohea extract composition of the present invention is considered to have been reported by nicotianamine contained in moroheia leaves that have been reported so far. It was also confirmed that it was not due to activity, but due to vasorelaxant action / vasodilatory action. That is, it was confirmed that the blood pressure lowering action of the proteolytic enzyme-treated Morohaya extract composition of the present invention was not due to nicotianamine contained in Morohaya leaves. The present invention has been completed based on these new findings.
  • Morohaya leaves from which hard stems had been removed were steam-heated and then crushed and dried with hot air to obtain dried Morohaya leaves.
  • Example 1 Example 1
  • Morohaya enzyme-treated extract B (Protease N Amano G treatment); Morohaya leaves from which hard stems had been removed were steam-heated and then crushed and dried with hot air to obtain dried Morohaya leaves.
  • Morohaya leaves from which hard stems had been removed were steam-heated and then crushed and dried with hot air to obtain dried Morohaya leaves.
  • the solution temperature was kept at 60 ° C. in a water bath, and 0.7% by weight of Samoaise Y 10 (manufactured by Yamato Kasei) was dissolved in a small amount of water and added to the raw dried moroya leaves. Thereafter, stirring was performed every 10 minutes while the liquid temperature was kept at 60 ° C.
  • the powders A, B, B ′ obtained in Comparative Example 1 and Examples 1 and 2 were dissolved in water for injection so as to be 100 mg / kg (body weight of SHR). ) was administered to the spontaneously hypertensive rat (S HRZHo, SPF) with a single gastric tube. Blood pressure was measured noninvasively before administration, 4 hours, 8 hours, and 24 hours after administration. The number of animals used in the test is shown in Table 2 below. In addition, although 7 mice were used for each group, data on individuals that clearly showed abnormal blood pressure fluctuations were deleted.
  • Figure 1 shows the changes in systolic blood pressure up to 24 hours after administration.
  • Figure 2 shows changes in diastolic blood pressure up to 24 hours after administration.
  • Figure 3 shows changes in heart rate up to 24 hours after administration.
  • Figure 4 shows the change in mean blood pressure up to 24 hours after administration.
  • Figure 5 shows the diurnal variation in systolic blood pressure of SHR up to 24 hours after administration.
  • B and B ′ showed strong blood pressure drop 4 hours after administration. Also in terms of mean blood pressure B and B ′ each showed a strong blood pressure drop 4 hours after administration.
  • Example 3 As is clear from the test results of the morohaya enzyme-treated extract of Example 1 (B) and Example 2 (B ′) above, the enzyme-treated extract obtained by treating morohaya leaves with a proteolytic enzyme is an enzyme-treated extract. It exhibited a stronger blood pressure lowering effect than the normal excision without treatment. In each figure, each value represents an average value.
  • Example 3
  • Figure 6 shows changes in systolic blood pressure and diastolic blood pressure up to 4 hours after administration.
  • a 7- to 10-week-old male SD rat was anesthetized with pentobarbitanore (50 m / kg, ip), and a body surface electrocardiogram (lead II) was recorded.
  • Cannula to femoral artery A whole body blood pressure was measured by inserting one.
  • a cannula for vasopressor administration was inserted into the femoral vein, and a catheter for sample injection was placed in the duodenum.
  • the state of anesthesia was maintained by pentobarbital administration as appropriate subcutaneously (guideline: 10 to 15 mgZkg / hr).
  • angiotensin I (1 g / kg, iv) was intravenously administered.
  • angiotensin I changed to angiotensin II by the action of angiotensin converting enzyme (ACE) in the living body, and increased blood pressure.
  • ACE angiotensin converting enzyme
  • the morohea enzyme-treated extract obtained in the same manner as in Example 1 was further purified and administered into the duodenum (50 mg / kg), at 30 and 60 minutes after administration.
  • the pressor response was confirmed by intravenous administration of the same dose of angiotensin I.
  • the enzyme-treated extract was purified by carrying out an adsorption treatment with a synthetic adsorbent, collecting the adsorbed fraction, treating it with a cation exchange resin, and then collecting the adsorbed fraction.
  • the pressor response by administration of angiotensin I at the time of administration of the enzyme-treated extract was +56.2 mmHg.
  • the pressor response was +57.7 mm Hg, +58.2 mmHg, and +58.2 mmHg, respectively. No change was observed. That is, the effect of inhibiting the conversion of angiotensin I to angiotensin II by administration of the moroheia enzyme-treated extract could not be confirmed. Therefore, it was confirmed that Moroheiya enzyme-treated extract does not have an AC E inhibitory action as already reported, but lowers blood pressure by another action mechanism. [Test Example 4]
  • a ring-shaped specimen was prepared using the thoracic aorta extracted from a male SD rat, and the blood vessel tension was measured in oxygenated 37 ° C Tyrode solution.
  • the morohea enzyme-treated extract obtained in the same manner as in Example 1 was further purified.
  • 0, 1 00 0, 3 00 ⁇ g / mL was added, and the presence or absence of a vasorelaxant action was observed.
  • the tension when Phenylephrine was added was 100%, and when the tension was lowered, the blood vessel was relaxed.
  • the enzyme-treated extract was purified by adsorption treatment with a synthetic resin adsorbent. The results are shown in Fig. 8. Each value represents the average soil standard error. N is 4. 'Result;
  • the moroheia enzyme-treated extract of the present invention showed a statistically significant relaxing action at 1 000 ⁇ g / mL or more. Therefore, it has been clarified that the action mechanism of the blood pressure lowering action of the extract of the present invention treated with the molohair enzyme is based on the vasorelaxant action. This is new knowledge about Morohaya. Industrial applicability
  • the morohae enzyme-treated extract of the present invention that is, the proteolytic enzyme-treated morohae extract composition, has an excellent blood pressure lowering action and can be ingested by oral administration because it has less peculiar taste to taste and odor. And as a medicine, It can be used effectively for various foods and drinks, especially health foods, health drinks and foods for specified health use. Furthermore, there is no fear of side effects and the economic and mental burden is light, so it can be taken safely and continuously for a long time, and is suitable as a prophylactic or therapeutic agent for hypertension.
  • the blood pressure lowering action and blood vessel relaxing action of the Morohaya enzyme-treated extract of the present invention are based on a mechanism of action different from that of nicotianamine contained in Morohaya, and new effects are expected. is there.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

L'invention concerne un agent anti-hypertenseur efficace pour traiter un patient souffrant d'hypertension, sans effet secondaire indésirable, très sûr et approprié pour une administration à long terme; un aliment, tel qu'un aliment naturel ou un additif nutritionnel et un aliment pour des utilisations de santé spécifiées comprenant la composition; et une boisson comprenant également ladite composition. L'invention concerne, plus particulièrement, une composition d'extrait de jute tossa (Corchorus olitorius L.) traitée par une protésae produite par traitement d'une feuille de jute tossa, un extrait de jute tossa, une solution d'extrait de jute tossa une purée de jute tossa avec une protéase. La composition présente une excellente activité d'anti-hypertenseur.
PCT/JP2008/069818 2007-10-31 2008-10-24 Composition d'extrait de jute tossa traitée par une protéase, procédé de production de la composition et agent anti-hypertenseur ou boisson/aliment comprenant ladite composition WO2009057725A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-284625 2007-10-31
JP2007284625 2007-10-31

Publications (1)

Publication Number Publication Date
WO2009057725A1 true WO2009057725A1 (fr) 2009-05-07

Family

ID=40591108

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/069818 WO2009057725A1 (fr) 2007-10-31 2008-10-24 Composition d'extrait de jute tossa traitée par une protéase, procédé de production de la composition et agent anti-hypertenseur ou boisson/aliment comprenant ladite composition

Country Status (1)

Country Link
WO (1) WO2009057725A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010270069A (ja) * 2009-05-22 2010-12-02 Ito En Ltd モロヘイヤ抽出物を有効成分とする血管病治療予防剤、及びこれを含有する飲食品
WO2011042979A1 (fr) * 2009-10-08 2011-04-14 小林製薬株式会社 Extrait préparé à partir de feuilles de du-zhong séchées, aliment transformé comprenant l'extrait et feuilles de du-zhong séchées
WO2011042978A1 (fr) * 2009-10-08 2011-04-14 小林製薬株式会社 Feuilles de du-zhong séchées, extrait de feuilles de du-zhong obtenu à partir des feuilles de du-zhong séchées et aliments transformés comprenant l'extrait de feuilles de du-zhong

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002165553A (ja) * 2000-11-30 2002-06-11 Komo:Kk ベイカリー食品
WO2005063245A1 (fr) * 2003-12-26 2005-07-14 Shimaya Co., Ltd. Composition destinee a baisser la tension arterielle
WO2006089921A1 (fr) * 2005-02-24 2006-08-31 Dsm Ip Assets B.V. Peptides abaissant la pression sanguine du glycomacropeptide
KR20060101056A (ko) * 2005-03-19 2006-09-22 윤연순 몰로키아를 함유한 구이 김 및 그 제조방법
JP2007043931A (ja) * 2005-08-09 2007-02-22 T Hasegawa Co Ltd カカオ酵素処理物およびその製造方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002165553A (ja) * 2000-11-30 2002-06-11 Komo:Kk ベイカリー食品
WO2005063245A1 (fr) * 2003-12-26 2005-07-14 Shimaya Co., Ltd. Composition destinee a baisser la tension arterielle
WO2006089921A1 (fr) * 2005-02-24 2006-08-31 Dsm Ip Assets B.V. Peptides abaissant la pression sanguine du glycomacropeptide
KR20060101056A (ko) * 2005-03-19 2006-09-22 윤연순 몰로키아를 함유한 구이 김 및 그 제조방법
JP2007043931A (ja) * 2005-08-09 2007-02-22 T Hasegawa Co Ltd カカオ酵素処理物およびその製造方法

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
EBIHARA A. ET AL.: "Molukhyia Chu no Trypsin Inhibitor ni Tsuite", BULLETIN OF SCHOOL OF NURSING, vol. 11, June 2007 (2007-06-01), pages 1 - 9 *
EL-DIN, A.M.M. ET AL.: "Chemical and technological studies on Jew's mallow leaves (Molukhyia)", EGYPTIAN JOURNAL OF FOOD SCIENCE, vol. 33, no. 1, 2005, pages 29 - 41 *
FAFUNSO,M. ET AL.: "Effect of age of some tropical vegetables on the amino acid composition of their extracted proteins", WEST AFRICAN JOURNAL OF BIOLOGICAL AND APPLIED CHEMISTRY, vol. 48, no. 2, 1975, pages 17 - 20 *
KIMOTO K. ET AL.: "Purification and Identification of Angiotensin I-Converting Enzyme Inhibitor from Morokheiya(Corchorus olitorius)", FOOD SCI TECHNOL INT TOKYO, vol. 4, no. 3, 1998, pages 223 - 226 *
KOKEAN Y. ET AL.: "Kennai Norin Suisanbutsu Koso Bunkaibutsu no Nyusankin Seiiku eno Eikyo to sono Hakko Eki no ACE Kassei Sogai ni Tsuite", REPORTS OF THE MIE PREFECTURAL SCIENCE AND TECHNOLOGY PROMOTION CENTER INDUSTRIAL RESEARCH, 15 October 2007 (2007-10-15), pages 152 - 154 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010270069A (ja) * 2009-05-22 2010-12-02 Ito En Ltd モロヘイヤ抽出物を有効成分とする血管病治療予防剤、及びこれを含有する飲食品
WO2011042979A1 (fr) * 2009-10-08 2011-04-14 小林製薬株式会社 Extrait préparé à partir de feuilles de du-zhong séchées, aliment transformé comprenant l'extrait et feuilles de du-zhong séchées
WO2011042978A1 (fr) * 2009-10-08 2011-04-14 小林製薬株式会社 Feuilles de du-zhong séchées, extrait de feuilles de du-zhong obtenu à partir des feuilles de du-zhong séchées et aliments transformés comprenant l'extrait de feuilles de du-zhong

Similar Documents

Publication Publication Date Title
JP4954990B2 (ja) グァバ葉エキス粉末及びその製造方法
US9399051B2 (en) Dipeptidyl peptidase-4 inhibitor
WO2009057725A1 (fr) Composition d'extrait de jute tossa traitée par une protéase, procédé de production de la composition et agent anti-hypertenseur ou boisson/aliment comprenant ladite composition
JP2011504464A (ja) 新規血圧降下組成物
JP2008050269A (ja) 経口摂取物
JP2008247888A (ja) 米麹を用いた降圧組成物
JP4716769B2 (ja) 血圧降下剤の製造方法
KR100842839B1 (ko) 가시오가피를 포함하는 혈압강하용 음료조성물 및 그의제조방법
JP4673071B2 (ja) 鉄吸着性高分子物質及び鉄含有高分子物質ならびにこれらの製造方法
CN107922458B (zh) 含有氨基酸及环状二肽的组合物
JP2002241305A (ja) 高血圧症予防・治療剤
JP7231313B2 (ja) 血圧を降下させるための組成物
KR100628539B1 (ko) 혈압상승 억제 및 혈압강하 효과가 있는 요구르트 조성물
KR102003934B1 (ko) 넙치 유래의 펩타이드를 포함하는 항고혈압용 조성물
WO2009057724A1 (fr) Composition de fraction adsorbée sur une résine synthétique dérivée de jute tossa à activité d'hypotenseur, agent hypotenseur ou aliment/boisson comprenant la composition de fraction adsorbée et procédé de production de la fraction adsorbée
JP2522367B2 (ja) アミノ酸類含有食品組成物
JP2008239521A (ja) アンジオテンシン変換酵素阻害剤およびその製造方法
Aluko Technology for the production and utilization of food protein-derived antihypertensive peptides: a review
WO2009107878A1 (fr) Extrait de légume contenant de l'adénine à haute concentration, boisson emballée contenant de l'adénine contenant l'extrait de légume, composition hypotensive pour usage oral contenant l'extrait de légume comme ingrédient actif et procédé pour le produire
CN101039685B (zh) 预防、抑制肝病的制剂和预防、抑制肝病的功能食品
CN1772039A (zh) 紫花地丁的利用物和利用方法
JP6770515B2 (ja) 血圧降下用組成物
JP2005239686A (ja) 脂肪燃焼促進組成物及び該組成物を含有する食品又は医薬品
JP2015193544A (ja) 葉菜蛋白質由来のａｃｅ阻害作用を有するペプチド
Najarian Changes in microbiological, physicochemical, biochemical and therapeutical characteristics of yoghurt upon the addition of selected medicinal herbs

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08843445

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08843445

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP